{"page_content": "Amgen 2017 Responsibility Highlights Report    2Our mission to serve patients is central \nto our strategy, which is focused on \ndiscovering, developing, manufacturing  \nand delivering innovative human therapeutics to treat some of the world\u2019s \nmost serious diseases. It is through these  \nefforts that we make our greatest contribution to society. \nAmgen has approximately 20,000 staff \nworldwide with a presence in 100 countries.  \nA biotechnology pioneer since 1980,  \nwe have reached millions of patients  \naround the world with our robust product portfolio of innovative medicines, and \nwe have a pipeline of medicines with \nbreakaway potential. \nAmgen focuses on areas of high unmet \nmedical need in cardiovascular disease, \noncology, bone health, nephrology, \nneuroscience and inflammation. Our staff \nstrive for solutions that provide the best possible health outcomes and dramatically \nimprove people\u2019s lives. Our medicines \ntypically address diseases for which there \nare limited treatment options, or they are \nmedicines that provide a viable option to \nwhat is otherwise available. \nAmgen has distinguished capabilities as a \nresearch and development innovator and as \na manufacturer of biologic medicines. We leverage tools such as advanced human \ngenetics to validate and identify human \ndisease targets. Through our biology-first \napproach, we seek to match disease targets \nwith the best modality or medicine from the \nstandpoint of optimal efficacy and safety. A \nworldwide leader in biologics manufacturing, \nAmgen has an outstanding track record of \nreliably delivering high-quality medicines to patients who need them.ABOUT AMGEN\nFOR MORE INFORMATION, VISIT ABOUT AMGEN  ON\nwww.amgen.com\n\u201cNever before have we been in \na better position to understand and combat human disease. \u201d \n\u2014 SEAN HARPER, EXECUTIVE VICE PRESIDENT,   \nRESEARCH AND DEVELOPMENT", "metadata": {"source": "NASDAQ_AMGN_2017.pdf", "page": 1, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}